While plasma NfL levels have shown promise as an early detection biomarker due to their significant elevation in AD and mild cognitive impairment patients compared to controls [33], CSF NfL concentrations have demonstrated a stronger association with specific pathological changes, such as amyloid-beta presence during the preclinical stage of sporadic AD [128]. This evidence concerns the gene NEFL and Alzheimer disease.